FASENRA 30mg solution for injection in pre-filled pen ASTRAZENECA ORIGINAL MEDICINE
Chemical substance: benralizumab
ATC code: R03DX10 • Respiratory system | Other systemic drugs for obstructive airway diseases
Active substance
Results for the substance benralizumab
2 results
About this active substance
Benralizumab is a medication used for the treatment of severe eosinophilic asthma that is inadequately controlled by other therapies. It is a monoclonal antibody that targets the interleukin-5 (IL-5) receptor, reducing the number of eosinophils, cells involved in airway inflammation.
The medication is administered via subcutaneous injection, usually once every four weeks for the first three doses, then once every eight weeks, as directed by a doctor.
Common side effects include headache, pharyngitis, fever, and injection site reactions. In rare cases, severe allergic reactions such as anaphylaxis may occur.
Benralizumab is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
The medication is administered via subcutaneous injection, usually once every four weeks for the first three doses, then once every eight weeks, as directed by a doctor.
Common side effects include headache, pharyngitis, fever, and injection site reactions. In rare cases, severe allergic reactions such as anaphylaxis may occur.
Benralizumab is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
-
-
FASENRA 30mg solution for injection in pre-filled syringe ASTRAZENECA ORIGINAL MEDICINE
Chemical substance: benralizumab
ATC code: R03DX10 • Respiratory system | Other systemic drugs for obstructive airway diseases